Dear Sirs:
Adverse drug reactions (ADR) may be dose-(type A) or non-dose-dependent (type B, hypersensitivity drug reactions/ HDR) [1] . HDR to non-steroidal anti-inflammatory drugs (NSAIDs) are reported to have a prevalence of 0.5-2.5% in the general population [2] . They most frequently manifest shortly after drug intake in the form of immediate-type reactions (i.e. urticaria, angio-oedema, dyspnoea, anaphylaxis); also, non-immediate-type reactions (i.e. maculopapular exanthema) may appear. Arachidonic acid mediators play a central role in immediate-type hypersensitivity to NSAIDs. In a subset of patients, the reactions may have an immunologically mediated, allergic background [2] .
In patients affected, there is often a need for safe alternative drugs, which leads to consultation of allergologists. Crossintolerance may appear, even to non-chemically related preparations [3] . Most patients with a history of hypersensitivity to selected NSAIDs, tolerate COX-2 inhibitors [4] , of which the use-as well as the long-term use of other NSAIDs-is limited, because of possible cardio-and cerebrovascular effects [5] .
Flupirtine, a non-opiate, centrally acting analgesic of the aminopyridine type (dosage orally 3×100-200 mg/day; AWD.pharma, Radebeul, Germany), constitutes a unique class within the group of NSAIDs and activates Kv7 (KCNQ/M) potassium channels [6] . Its muscle relaxant properties make it popular for orthopaedic use, but it is also used for other pain conditions or in neurodegenerative syndromes (i.e. multiple sclerosis) [6] . Anti-parkinsonian and other motor effects relying on its NMDA-antagonistic effects have been demonstrated [7] . Most frequent ADR in flupirtine-treated patients (n=110; 3× 100 mg/day) were vertigo (13%) and nausea (9%), but rates of these ADR were significantly lower than in a control group treated with tramadol (n=110) [8] . There are no studies on its long-term cerebro-or cardiovascular effects [9] .
As flupirtine seems to be an interesting alternative drug in patients with a history of HDR to NSAIDs, we wanted to assess its tolerability with regard to hypersensitivity reactions in this group of patients.
A retrospective medical chart review involved all patients who had diagnostic work-up, including a single blind placebo controlled oral provocation test (SB-OPT) because of a history of HDR to NSAIDs in our University Department for Dermatology and Allergology in 2006-2007. All patients underwent allergological skin tests and evaluation of serum tryptase to exclude underlying systemic mastocytosis favouring immediate-type reactions. SB-OPT started with 12.5% of one drug dose and was increased every 30-60 min (25%, 50%, 100%; i.e. in flupirtine 12.5 mg, 25 mg, 50 mg, 100 mg).
The drugs tested were chosen according to:
1. Their analgesic potency 2. The choice of the referring doctor 3. The eliciting drug at previous HDR with regard to possible cross reactions Flupirtine was the most frequently applied alternative drug at SB-OPT (in 83% of 70 patients; see all drugs applied in Table 1 ). SB-OPT elicited mild nausea in 3 patients after intake of tramadol (known pharmacological reaction). ADR classified as being of hypersensitive origin were noticed in 6 out of 149 SB-OPT with an alternative and in 1 out of 6 SB-OPT with the suspect drug.
Within 4-34 months (median 13) after SB-OPT patients were contacted for a standardised interview, considering:
1. Any use of the tested drug since last SB-OPT 2. Reason for use, if any 3. Tolerance 4. Efficiency Seventy patients (58 female, 12 male; age at OPT 52 years, range 17-80) had reported on the history of 131 HDR (n=104 immediate-type, n=25 non-immediate type, n=2 unclear; median age at HDR 49 years, range 12-80). The median interval between HDR and SB-OPT was 12 months (range 1-120). The drugs suspected of eliciting HDRs (more than one drug in 37 out of 70; 53%) were: acetylic salicylic acid (ASA; n=29; 22.1%), ibuprofen (n=25; 19.1%), acetaminophen (n=16; 4.6%), diclophenac (n=16; 4.6%), metamizole (n=15; 4.3%), and others (n=30; 22.9%). Skin testing and serum tryptase levels (ruling out underlying mastocytosis in immediate-type reactions) were of no avail.
Thirty-eight patients out of 70 (63.3%) responded to the interview, of whom 25 out of 38 (65.8%) reported a new drug intake of any of the tested drugs tolerated at SB-OPT because of the following 31 events: bone/muscle pain (15 out of31, 48.3%), tooth pain (6 out of 31; 19.4%), headache (5 out of 31; 16%), and flu/others (5 out of 31, 16%). In those patients, flupirtine (9/31, 29%), was taken exclusively because of musculoskeletal pain. The following other drugs were taken: acetaminophen (9/31, 29%), COX-2 inhibitors (5/31, 16%), other NSAIDs (5/31; 16%), and opioid analogues (3/31; 10%). No new hypersensitivity reaction was noticed in any of the patients to any of the drugs. Analgesic efficacy was judged as being sufficient in 23 out of 31 events (74%), and in all patients who had received flupirtine.
In summary, SB-OPT led to the identification of safe alternative drugs in patients with a history of hypersensitivity to NSAIDs. The good tolerability of flupirtine in this group of patients may as well be explained by its lack of effect on COX inhibition as by a presumed less immunogenic effect. According to our data, flupirtine should be taken into consideration as an alternative drug in patients with hypersensitivity to NSAIDs suffering from moderate to severe pain, especially of the musculoskeletal system. Further investigations are required to confirm our data and should also focus on the question: does flupirtine have a superior drug profile compared with other NSAIDs regarding cerebro-/cardiovascular and renal effects? 
